| 6.81 -0.15 (-2.16%) | 09-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Portage Biotech Inc., operating through its various subsidiaries, focuses on the discovery and advancement of novel pharmaceutical and biotechnological products. The company's extensive pipeline includes several key therapeutic candidates and platforms. Among these are IMM60, an activator for iNKT cells; IMM65, a specialized PLGA-nanoparticle integrated with a NY-ESO-1 peptide vaccine; and INT230-6, which is currently in Phase I/II clinical trials for addressing solid tumors. Additionally, their portfolio features STING, a small molecule designed to bind to the stimulator of interferon genes in cancer; CellPorter, a platform utilizing cell-permeable peptides derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology aimed at re-establishing immune balance after acute vital organ injury, such as acute kidney injury. The company also dedicates efforts to nanolipogel technology for its applications in immuno-oncology. It is developing antibodies against a novel T-cell for potential use as both monotherapy and combination therapy in treating solid and haematological malignancies. Furthermore, Portage Biotech is advancing antibodies that target the inflammatory tumor microenvironment and tumor-infiltrating immune cells, alongside an investigational FOXO4-P53 modulator and a C-RAF inhibitor. Portage Biotech Inc. is headquartered in Tortola, British Virgin Islands.
Wed, 03 Sep 2025
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem - GlobeNewswire
Wed, 03 Sep 2025
Portage Biotech Inc. will Change its Ticker to ATON from PRTG - marketscreener.com
Mon, 28 Apr 2025
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times
Mon, 28 Apr 2025
Is Portage Biotech Inc. Stock Poised for a Rally? - timothysykes.com
Thu, 24 Apr 2025
Portage Biotech (PRTG) Stock Price, News & Analysis - Stock Titan
Fri, 28 Mar 2025
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|